Health Discovery Corporation (OTCBB: HDVY) (HDC) announced today the appointment of Maher Albitar, M.D., a world renowned cancer scientist and inventor, to the position of Chief Medical Officer. Until recently, Dr. Albitar was the Medical Director of Hematology and Oncology and Chief of Research and Development at Quest Diagnostics Nichols Institute (NYSE: DGX), San Juan Capistrano, Calif. Prior to Quest Diagnostics, Dr. Albitar was a tenured full professor at the M.D. Anderson Cancer Center and the University of Texas, where he served as chief of the hematopathology of the leukemia section with joint appointment in the clinical leukemia department.
“Dr. Albitar is a globally respected cancer researcher with the unique combination of both academic and commercial experience having held high level appointments at Quest Diagnostics, the largest commercial clinical laboratory in the world, as well as M.D. Anderson Cancer Center, voted the top hospital in the nation for cancer care, according to the U.S. News & World Report annual 'America's Best Hospitals,'” said Stephen D. Barnhill, M.D., Chairman and CEO at Health Discovery Corporation. “We’re thrilled to have Dr. Albitar join our team and lead our molecular diagnostic and medical imaging discovery, development and commercialization program.”
“For a long-time, I’ve admired Dr. Barnhill and his cutting-edge work in addressing the urgent need for effective cancer diagnostic test development,” said Dr. Albitar. “I am very impressed with HDC’s progress in prostate cancer, breast cancer, colon cancer, leukemia, pancreatic cancer and melanoma, and I am looking forward to working closely with the distinguished team at HDC to increase the pipeline of cancer diagnostic and prognostic tests and prepare these tests for commercialization.”
Dr. Albitar will immediately help position the Company to expand its pipeline of molecular diagnostic and medical imaging tests for cancer using the Company’s patented Support Vector Machine technology. The Company holds 43 issued patents and 32 pending patents related to its SVM and SVM-RFE development tools.